1 Examining the immune tumor microenvironment of endometrial cancer patients treated with pembrolizumab plus lenvatinib
Our aim is to examine the immune microenvironment of endometrial cancer (EMCA) patients treated with pembrolizumab plus lenvatinib (P+L) that could contribute to increased time on treatment. This may help inform patient selection and identify new therapeutic targets among aggressive endometrial canc...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology reports 2023-08, Vol.48, p.S1-S1 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Our aim is to examine the immune microenvironment of endometrial cancer (EMCA) patients treated with pembrolizumab plus lenvatinib (P+L) that could contribute to increased time on treatment. This may help inform patient selection and identify new therapeutic targets among aggressive endometrial cancer subtypes.
229 endometrial cancer patients were analyzed using Next-Gen sequencing of the DNA (NextSeq, 592 genes or NovaSeq, WES) and RNA (NovaSeq, WTS) (Caris Life Sciences, Phoenix, AZ. Time on treatment (TOT) was obtained from insurance claims and Kaplan-Meier estimates were calculated for molecularly defined patient cohorts as the time of first to last treatment of P+L. Responders (R) and non-responders (NR) were defined by treatment for > or |
|---|---|
| ISSN: | 2352-5789 2352-5789 |
| DOI: | 10.1016/S2352-5789(23)00222-9 |